Drug Trial Radar · NCT04728711
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 9, 2021
Primary completion
Jan 18, 2022
Study completion Jan 18, 2022
Sponsor
- Lead sponsor
- Aldeyra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects with Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Conditions
- Atopic Asthma
Interventions
ADX-629Drug
ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
PlaceboDrug
Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was Day 1 - Day 7 for each treatment intervention.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliantha Research
Mississauga, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.